Compare Levi Strauss & Co. (LEVI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Summit Therapeutics Inc — how do they compare? Levi Strauss & Co. trades at $22.44 (market cap $8.64B), while Summit Therapeutics Inc trades at $14.03 (market cap $12.06B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Levi Strauss & Co. pays a 2.85% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LEVI | SMMT | |
|---|---|---|
Market Cap | $8.64B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $26.98 |
52-Week Low | $17.92 | $12.55 |
Enterprise Value | $9.95B | $11.39B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $22.42, down 1.41% on the day, with a bearish technical signal but strong fundamentals including a 9.66% net income margin and 29.31% ROE. Recent Q2 2026 earnings beat expectations, and the company raised its full-year outlook, driven by direct-to-consumer growth and digital strategies. Cash flow trends show improvement, with net cash flow turning positive in 2024 and 2025 after prior years of outflows.
The stock presents a compelling value with a P/E of 16.03 and analyst consensus price target of $27.88, implying 24% upside. Risks include recent cybersecurity breaches, tariff pressures, and execution challenges in DTC expansion. Investor sentiment is mixed due to near-term headwinds despite solid earnings performance.
Summit Therapeutics (SMMT) trades at $15.10, showing minimal daily change. The technical outlook is bullish based on moving averages, though the stock faces critical FDA review for its lead drug ivonescimab by November 2026. Recent news includes regulatory approval in China and expanded clinical trials, but the company reports significant losses and negative cash flow from operations, highlighting its pre-revenue biotech status.
The investment case hinges on ivonescimab's regulatory success, with a consensus price target of $24.18 implying substantial upside. However, high execution risk, ongoing losses, and a shareholder investigation present significant challenges. The stock offers high-risk, high-reward potential for speculative investors banking on positive clinical and regulatory outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
